Tag Archives: treatment

fightcrc-researchupdate-tas-102

Another treatment option coming down the pike: TAS-102

Another treatment option coming down the pike: TAS-102

Fight Colorectal Cancer stays actively involved in the research process from beginning to end. Part of our role in research is monitoring the progress of new drugs – drugs that may be used in treatment plans of colorectal cancer in the future. We actively work with drug companies to stay up-to-date on the latest treatments so that we can let patients and families know what’s happening in the science of colorectal cancer. For the last year, Fight Colorectal Cancer staff have tracked the progress of the drug TAS-102 – an oral chemo drug currently being evaluated in clinical trials for patients with metastatic refractory colorectal cancer. At the ESMO World

Important information to know – from screening to diagnosis for colorectal cancer

Tips From a Member of Our Medical Advisory Board Al B. Benson III, MD, FACP FASCO is Professor of Medicine, Feinberg School of Medicine,  and Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center, Northwestern University One of the nation’s most respected experts in colorectal cancer, Dr. Benson has supported and worked with Fight Colorectal Cancer for years as an active member of our Medical Advisory Board.   Written by Dr. Al Benson, March 18 2013, Chicago, Illinois Although March is Colorectal Cancer Awareness Month, this disease is so frequent yet in most cases preventable that we should be striving every month of the year to make even more people

FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a drought of 5 years in approving new treatments for metastatic colorectal cancer (mCRC). Regorafenib was placed into the  FDA’s “fast-track” approval process after the international, multicenter Phase III CORRECT trial  showed improved survival (from 5 to 6.4 months) in all mCRC patients, including those having both non-mutated and mutated KRAS types.

July 2012 Webinar: Treating Late Stage Colorectal Cancer

Dr. Leonard Saltz of the Memorial Sloan-Kettering Cancer Center explains what treatment options exist for patients with late stage disease. Unfortunately, far too many patients will still hear their doctors say, “We are running out of options.” Fight Colorectal Cancer Director of Patient Information Services Kim Ryan hosted this informative webinar while riding out a typical summer east coast storm – some of the audio cut out towards the end. We apologize in advance for the gaps. View and download the slides

Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who will benefit the most from treatments, as well as those who might not be helped at all. (Note, many of these issues will be discussed in detail on our upcoming patient webinar.) Highlights: While adding oxaliplatin to 5-FU improves five year survival slightly for stage II colon cancer, it increases side effects, particularly tingling and numbness in the feet.  An analysis of several NSABP trials found that two or three

Top